FilingSEC EDGAR6-K
RedHill Biopharma Acquires Commercialization Rights to Rebyota and Clenpiq from Ferring Pharmaceuticals
· SEC accepted
StageAcquisition Completed
Filing content
The company has acquired exclusive commercialization rights to two FDA-approved gastrointestinal drugs for an upfront payment of $12 million, strengthening its commercial portfolio.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…